Abstract：
We assessed the vaccination effectiveness (VE) of multicomponent meningococcal serogroup B (4CMenB) vaccine against gonorrhea among people living with HIV (PLWH) with a previous diagnosis of sexually transmitted infection.
Unmatched case-control study on men who have sex with men living with HIV, in care at San Raffaele Scientific Institute, Milan, Italy, with gonorrhea, syphilis, chlamydia, or anal human papillomavirus between July 2016 (beginning of 4CMenB vaccination) and February 2021 (date of freezing). For the analysis, cases were people with ≥1 gonorrhea infection since July 2016, and controls were people with ≥1 syphilis, chlamydia, or anal human papillomavirus infection since July 2016. Logistic regression was used to provide the estimate of 4CMenB VE against gonorrhea.
Included people living with HIV were 1051 (103 cases, 948 controls); 349 of 1051 (33%) received 2 doses of 4CMenB vaccination. The median follow-up was 3.8 years (2.1-4.3 years). The unadjusted estimate for VE against gonorrhea was 42% (95% confidence interval, 6%-64%; P = 0.027). Logistic regression showed that VE against gonorrhea remained significant (44%; 95% confidence interval, 9%-65%; P = 0.020) after adjusting for some factors that might have a potential influence on VE or those with significant unbalanced distributions between cases and controls at univariable analysis.
4CMenB vaccination is associated with a lower risk of gonorrhea in the setting of men who have sex with men living with HIV with a previous sexually transmitted infection.
Unmatched case-control study on men who have sex with men living with HIV, in care at San Raffaele Scientific Institute, Milan, Italy, with gonorrhea, syphilis, chlamydia, or anal human papillomavirus between July 2016 (beginning of 4CMenB vaccination) and February 2021 (date of freezing). For the analysis, cases were people with ≥1 gonorrhea infection since July 2016, and controls were people with ≥1 syphilis, chlamydia, or anal human papillomavirus infection since July 2016. Logistic regression was used to provide the estimate of 4CMenB VE against gonorrhea.
Included people living with HIV were 1051 (103 cases, 948 controls); 349 of 1051 (33%) received 2 doses of 4CMenB vaccination. The median follow-up was 3.8 years (2.1-4.3 years). The unadjusted estimate for VE against gonorrhea was 42% (95% confidence interval, 6%-64%; P = 0.027). Logistic regression showed that VE against gonorrhea remained significant (44%; 95% confidence interval, 9%-65%; P = 0.020) after adjusting for some factors that might have a potential influence on VE or those with significant unbalanced distributions between cases and controls at univariable analysis.
4CMenB vaccination is associated with a lower risk of gonorrhea in the setting of men who have sex with men living with HIV with a previous sexually transmitted infection.
摘要：
背景：我们评估了先前诊断为性传播感染（STI）的HIV感染者（PLWH）中针对淋病的多组分脑膜炎球菌血清群B（4CMenB）疫苗的疫苗接种有效性（VE）。
方法：对男男性行为者（MSM）感染艾滋病毒的无匹配病例对照研究，在圣拉斐尔科学研究所接受护理，米兰,意大利,淋病，梅毒,2016年7月（4CMenB疫苗接种开始）至2021年2月（冻结日期）之间的衣原体或肛门HPV。为了分析，病例为2016年7月以来淋病感染≥1例，对照组为梅毒≥1例，衣原体,或自2016年7月以来肛门HPV感染。使用Logistic回归提供4CMenBVE对淋病的估计。
结果：包括PLWH1051例（103例，948个对照）；349/1051（33%）接受了两剂4CMenB疫苗接种。中位随访时间为3.8年（2.1-4.3）。针对淋病的VE的未调整估计值为42％（95CI6-64；p=0.027）。Logistic回归显示VE对淋病的治疗效果仍然显著(44%，95CI9-65；p=0.020）在调整了一些可能对VE产生潜在影响的因素或在单变量分析中病例和对照之间具有显着不平衡分布的因素后。
结论：4CMenB疫苗接种与先前患有性传播感染的HIVMSM的淋病风险较低相关。
方法：对男男性行为者（MSM）感染艾滋病毒的无匹配病例对照研究，在圣拉斐尔科学研究所接受护理，米兰,意大利,淋病，梅毒,2016年7月（4CMenB疫苗接种开始）至2021年2月（冻结日期）之间的衣原体或肛门HPV。为了分析，病例为2016年7月以来淋病感染≥1例，对照组为梅毒≥1例，衣原体,或自2016年7月以来肛门HPV感染。使用Logistic回归提供4CMenBVE对淋病的估计。
结果：包括PLWH1051例（103例，948个对照）；349/1051（33%）接受了两剂4CMenB疫苗接种。中位随访时间为3.8年（2.1-4.3）。针对淋病的VE的未调整估计值为42％（95CI6-64；p=0.027）。Logistic回归显示VE对淋病的治疗效果仍然显著(44%，95CI9-65；p=0.020）在调整了一些可能对VE产生潜在影响的因素或在单变量分析中病例和对照之间具有显着不平衡分布的因素后。
结论：4CMenB疫苗接种与先前患有性传播感染的HIVMSM的淋病风险较低相关。
